Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
Immunotherapy

David S Hong, ESMO 2021: Gavocabtagene Autoleucel Dose Escalation in Refractory Mesothelin-expressing Solid Tumors (PART ONE)

Copy Link
Published Online: Oct 11th 2021

touchONCOLOGY joins Professor David S Hong (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) at ESMO 2021 to discuss the safety and activity of gavocabtagene autoleucel in a dose-escalation study in patients with refractory ovarian cancer, malignant mesothelioma, cholangiocarcinoma or non-small cell lung cancer. To view Part Two, click here.

Questions
1. What is Gavo-cel and what is its mechanism of action? (00:31-01:37)
2. Could you tell us a little about the dose escalation study you are presenting? (01:37-03:17)
3. What have been the efficacy and safety findings to date? (03:17-07:36)

Disclosures: David Hong has received research (institution) and grant funding (institution) from: AbbVie, Adaptimmune, Aldi-Norte, Amgen, AstraZeneca, Bayer, BMS, Daiichi-Sankyo, Deciphera, Eisai, Erasca, Fate Therapeutics, Genentech, Genmab, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, Medimmune, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, SeaGen, Takeda, Turning Point Therapeutics, Verstatem and VM Oncology. He has received travel and accommodation expenses from: Bayer, Genmab, AACR, ASCO, SITC and Telperian. He has received consulting, speaker or advisory role fees from: Adaptimmune, Alpha Insights, Acuta, Alkermes, Amgen, Aumbiosciences, Atheneum, Axiom, Barclays, Baxter, Bayer, Boxer Capital, BridgeBio, CDR-life AG, COR2ed, COG, Ecor1, Genentech, Gilead, GLG, Group H, Guidepoint, HCW Precision, Immunogen, Infinity, Janssen, Liberium, Medscape, Numab, Oncologia Brasil, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, Seattle Genetics, ST Cube, Takeda, Tavistock, Trieza Therapeutics, Turning Point, WebMD and Ziopharm. He has other ownership interests from: OncoResponse (Founder), Telperian Inc (Advisor).

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson

Filmed in coverage of the ESMO 2021 Annual Meeting.

Share this Video
Related Videos In Immunotherapy
Immunotherapy
Developed by Touch
Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
Watch Time: 15 mins

We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment. Questions Could you give us a brief overview of the current approval status of CAR-T […]

Immunotherapy
Michael Atkins: Safe and Effective Use of Immune Checkpoint Inhibitors in Patients with Cancer

Dr Michael Atkins (MedStar Georgetown University Hospital, Washington, DC, USA) shares three areas for development to help improve the safe and effective use of immune checkpoint inhibitors. 1. Having a rational approach to stopping therapy (00:50-02:20) 2. An improved understanding of toxicity and response (02:20-04:25) 3. The role of combining and sequencing immunotherapy with standard […]

Immunotherapy
Lyudmila A Bazhenova, WCLC 2021: Challenges of Widespread Immunotherapy

touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer. Questions 1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51) 2. What are […]

Trending In Immunotherapy:

Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
Immunotherapy
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72